Caseware UK (AP4) 2024.0.164 2024.0.164 0falsetrue2024-01-01falseNo description of principal activity5The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false NI681133 2024-01-01 2024-12-31 NI681133 2023-01-01 2023-12-31 NI681133 2024-12-31 NI681133 2023-12-31 NI681133 c:Director1 2024-01-01 2024-12-31 NI681133 c:Director2 2024-01-01 2024-12-31 NI681133 d:ComputerEquipment 2024-01-01 2024-12-31 NI681133 d:ComputerEquipment 2024-12-31 NI681133 d:ComputerEquipment 2023-12-31 NI681133 d:ComputerEquipment d:OwnedOrFreeholdAssets 2024-01-01 2024-12-31 NI681133 d:PatentsTrademarksLicencesConcessionsSimilar 2024-12-31 NI681133 d:PatentsTrademarksLicencesConcessionsSimilar 2023-12-31 NI681133 d:CurrentFinancialInstruments 2024-12-31 NI681133 d:CurrentFinancialInstruments 2023-12-31 NI681133 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 NI681133 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 NI681133 d:ShareCapital 2024-12-31 NI681133 d:ShareCapital 2023-12-31 NI681133 d:SharePremium 2024-12-31 NI681133 d:SharePremium 2023-12-31 NI681133 d:RetainedEarningsAccumulatedLosses 2024-12-31 NI681133 d:RetainedEarningsAccumulatedLosses 2023-12-31 NI681133 c:OrdinaryShareClass1 2024-01-01 2024-12-31 NI681133 c:OrdinaryShareClass1 2024-12-31 NI681133 c:OrdinaryShareClass1 2023-12-31 NI681133 c:FRS102 2024-01-01 2024-12-31 NI681133 c:AuditExempt-NoAccountantsReport 2024-01-01 2024-12-31 NI681133 c:FullAccounts 2024-01-01 2024-12-31 NI681133 c:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 NI681133 d:PatentsTrademarksLicencesConcessionsSimilar d:ExternallyAcquiredIntangibleAssets 2024-01-01 2024-12-31 NI681133 2 2024-01-01 2024-12-31 NI681133 d:PatentsTrademarksLicencesConcessionsSimilar d:OwnedIntangibleAssets 2024-01-01 2024-12-31 NI681133 e:PoundSterling 2024-01-01 2024-12-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: NI681133










AilseBio Limited (formerly Ailsevax Limited)








Unaudited

Financial statements

Information for filing with the registrar

For the Year Ended 31 December 2024

 
Ailsebio Limited
Registered number: NI681133

Balance Sheet
As at 31 December 2024

2024
2023
Note
£
£

Fixed assets
  

Intangible assets
 4 
25,994
10,451

Tangible assets
 5 
12,375
20,792

  
38,369
31,243

Current assets
  

Debtors: amounts falling due within one year
 6 
163,024
125,092

Cash at bank and in hand
 7 
178,735
568,353

  
341,759
693,445

Creditors: amounts falling due within one year
 8 
(82,820)
(48,048)

Net current assets
  
 
 
258,939
 
 
645,397

Total assets less current liabilities
  
297,308
676,640

  

Net assets
  
297,308
676,640


Capital and reserves
  

Called up share capital 
 9 
798
798

Share premium account
  
937,047
937,047

Profit and loss account
  
(640,537)
(261,205)

  
297,308
676,640

img216e.png
Page 1

 
Ailsebio Limited
Registered number: NI681133

Balance Sheet (continued)
As at 31 December 2024

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 13 March 2025.




Paul Gerard Kerr
David Moore
Director
Director

The notes on pages 3 to 8 form part of these financial statements.

img5746.png
Page 2

 
Ailsebio Limited
 

 
Notes to the Financial Statements
For the Year Ended 31 December 2024

1.


General information

Ailsevax Limited is a private company limited by shares incorporated in Northern Ireland. The registration number and address of the registered office are given in the company information section of these financial statements.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Going concern

The Director's of Ailsevax Limited have reviewed the resources available and believe that the company has adequate resources to continue in operational existence for the foreseeable future.
The Director's continue to adopt the going concern basis in preparing their financial statements.

 
2.3

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of Comprehensive Income within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

img35d5.png
Page 3

 
Ailsebio Limited
 

 
Notes to the Financial Statements
For the Year Ended 31 December 2024

2.Accounting policies (continued)

 
2.4

Research and development

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which range from 3 to 6 years.
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

 
2.5

Government grants

Grants are accounted under the accruals model as permitted by FRS 102. Grants relating to expenditure on tangible fixed assets are credited to profit or loss at the same rate as the depreciation on the assets to which the grant relates. The deferred element of grants is included in creditors as deferred income.
Grants of a revenue nature are recognised in the Statement of Comprehensive Income in the same period as the related expenditure.

 
2.6

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.7

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

 
2.8

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.


img06d4.png
Page 4

 
Ailsebio Limited
 

 
Notes to the Financial Statements
For the Year Ended 31 December 2024

2.Accounting policies (continued)

 
2.9

Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

 
2.10

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Computer equipment
-
33.3%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.11

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.12

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.13

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

img4702.png
Page 5

 
Ailsebio Limited
 

 
Notes to the Financial Statements
For the Year Ended 31 December 2024

3.


Employees

The average monthly number of employees, including directors, during the year was 5 (2022 - 4). 


4.


Intangible assets




Patents

£



Cost


At 1 January 2024
10,995


Additions
17,939



At 31 December 2024

28,934



Amortisation


At 1 January 2024
544


Charge for the year
2,396



At 31 December 2024

2,940



Net book value



At 31 December 2024
25,994



At 31 December 2023
10,451



img4168.png
Page 6

 
Ailsebio Limited
 

 
Notes to the Financial Statements
For the Year Ended 31 December 2024

5.


Tangible fixed assets





Computer equipment

£



Cost or valuation


At 1 January 2024
27,011


Additions
755



At 31 December 2024

27,766



Depreciation


At 1 January 2024
6,219


Charge for the year
9,172



At 31 December 2024

15,391



Net book value



At 31 December 2024
12,375



At 31 December 2023
20,792


6.


Debtors

2024
2023
£
£


Other debtors
100,089
96,013

Prepayments and accrued income
62,935
29,079

163,024
125,092



7.


Cash and cash equivalents

2024
2023
£
£

Cash at bank and in hand
178,735
568,353

178,735
568,353


img6413.png
Page 7

 
Ailsebio Limited
 

 
Notes to the Financial Statements
For the Year Ended 31 December 2024

8.


Creditors: Amounts falling due within one year

2024
2023
£
£

Trade creditors
68,193
31,341

Other taxation and social security
4,823
9,733

Other creditors
2,964
1,774

Accruals and deferred income
6,840
5,200

82,820
48,048



9.


Share capital

2024
2023
£
£
Allotted, called up and fully paid



79,804 (2023 - 79,804) Ordinary shares of £0.01 each
798.04
798.04



10.


Pension commitments

The Company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Company  in an independently administered fund. The pension cost charge represents contributions payable by the Company to the fund and amounted to £7,579 (2023 - £5,634). Contributions totalling £1,362 (2023 - £1,113) were payable to the fund at the balance sheet date and are included in creditors.


img3e6a.png
Page 8